An open label, randomized phase 2 trial assessing the impact of food on the tolerability of abemaciclib in patients with advanced breast cancer

PURPOSE: Abemaciclib, a CDK4 & 6 inhibitor, is indicated for advanced breast cancer treatment. Diarrhea is a frequently associated adverse event of abemaciclib. The study objective was to investigate if food intake impacts local gastrointestinal toxicity. METHODS: This Phase 2 study (I3Y-MC-JPCP...

Descripción completa

Detalles Bibliográficos
Autores principales: Lim, Elgene, Boyle, Frances, Okera, Meena, Loi, Sherene, Goksu, Sema Sezgin, van Hal, Gertjan, Chapman, Sonya C., Gable, Jonathon Colby, Chen, Yanyun, Price, Gregory L., Hossain, Anwar M., Gainford, M. Corona, Ezquerra, Meritxell Bellet
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2022
Materias:
Clinical Trial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9464758/
https://www.ncbi.nlm.nih.gov/pubmed/35915198
http://dx.doi.org/10.1007/s10549-022-06690-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9464758/
https://www.ncbi.nlm.nih.gov/pubmed/35915198
http://dx.doi.org/10.1007/s10549-022-06690-5

Ejemplares similares